Shree Ganesh Remedies Share Price

Shree Ganesh Remedies Limited was originally incorporated as a private company as Shree Ganesh Remedies Private Limited at Ahmedabad on April 27, 1995. Subsequently the Company was converted into a Public Limited named Shree Ganesh Remedies Limited on July 28, 2017. The Company has carved a niche in the industry of manufacturing pharmaceutical intermediates and fine chemicals.Shree Ganesh Remedies is a ISO 9001:2015, ISO 14001:2015 BS and OHSAS 18001:2007 certified Company and is engaged in manufacturing and dispatch of drug intermediates and chemicals like amine hydrochloride and specialty fine chemicals for pharmaceutical industry. The Company manufactures products relating to antipsychotic, antiseptic, deprotonation reactions, hyperlipidemia, alzheimers and antiviral. The Products are manufactured for export market and also for domestic and foreign markets. The Company entered the International market in 2006 and are on regular basis exporting its products to various countries.The manufacturing facility is divided into three manufacturing plants namely Plant I, II and III spread across 9715 square meters having different product manufacturing capabilities and process. The manufacturing process is supported by Total Quality Management techniques and is supervised through various quality control equipments and qualified personnel. The Products are manufactured for export market and also for domestic and foreign markets.In October 2017, the Company came up with a Public Issue of 23,76,000 Fresh Equity Shares by raising equity funds aggregating to Rs 8.56 Crores.In Unit I, Plant 5 was commissioned and made operational in 2018. In 2019, the Company started commercial production at the new production plant at GIDC, Ankleshwar. It acquired Ashok Pharma Chem (Partnership Firm) on December 24, 2019. In 2020, it launched New Advance Pharmaceutical Intermediates substituting the import intermediates. High Pressure Reaction Block was commissioned in 2023.The Company commissioned Block 8 in 2025. In FY 2026, it completed the pilot trials for CRAMS projects, commissioned a new pilot facility and advanced Block 7 towards commissioning.